title: Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression.
abstract: OBJECTIVE
  CXCR4 is overexpressed on tumor cells from many types of human cancers. A high level of CXCR4 expression often correlates with poor prognosis, chemotherapy resistance, and metastasis. The development of CXCR4-specific radiotracers for positron emission tomography (PET) imaging will allow in vivo evaluation of receptor expression level for diagnosis or therapeutic evaluation.
  
  
  METHODS
  Two new (18)F-labeled radiotracers based on an Ac-TC14012 peptide, [(18)F]FP-Ac-TC14012 and [(18)F]FB-Ac-TC14012, were synthesized and characterized. The affinities of the 2-fluoropropionate (FP)-conjugated or 4-fluorobenzoate (FB)-conjugated peptides to CXCR4-transfected Chinese hamster ovarian (CHO) cells were evaluated in a competitive binding assay with [(125)I]CXCL12 radioligand. The cell uptake and retention of [(18)F]FP-labeled and [(18)F]FB-labeled peptides were measured. The tumor targetability and pharmacokinetics of these two tracers were also evaluated by microPET imaging and biodistribution studies.
  
  
  RESULTS
  The labeled peptides retained high binding affinity to CXCR4 and showed much higher uptake in CXCR4-positive CHO cells than in CXCR4-negative cells in vitro. The smaller and more hydrophilic [(18)F]FP prosthetic group resulted in higher affinity and lower nonspecific cell uptake compared to the [(18)F]FB-labeled peptide. Both radiotracers showed much higher accumulation in CXCR4-positive than CXCR4-negative tumor xenografts in mice and allowed clear visualization of CXCR4 expression by PET. Among the two, [(18)F]FP-Ac-TC14012 showed higher tumor uptake and better tumor-to-background contrast. Unlike their N-terminal 4-F-benzoate analogs, these two tracers had minimal blood retention, likely due to reduced red blood cell binding. Metabolic organs, such as the liver and kidney, also showed high uptake. When blocked with low-dose cold peptide (10 μg), the tumor uptake was significantly increased, most likely due to the increased concentration in blood circulation, as evidenced by decreased liver uptake.
  
  
  CONCLUSIONS
  These results demonstrate that the [(18)F]FP-labeled Ac-TC14012 peptide with high tumor uptake, low nonspecific binding, and good tumor-to-background contrast promises [(18)F]FP-Ac-TC14012 as a PET tracer for in vivo PET imaging of CXCR4 expression.
authors: Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA.
authors: Xiao-Xiang
authors: XX
authors: Zhang
authors: Zhongchan
authors: Z
authors: Sun
authors: Jinxia
authors: J
authors: Guo
authors: Zhe
authors: Z
authors: Wang
authors: Chenxi
authors: C
authors: Wu
authors: Gang
authors: G
authors: Niu
authors: Ying
authors: Y
authors: Ma
authors: Dale O
authors: DO
authors: Kiesewetter
authors: Xiaoyuan
authors: X
authors: Chen
mesh_terms: D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics*; D051379:Mice; D008819:Mice, Nude; D057054:Molecular Imaging / Q000379:methods*; D009369:Neoplasms / Q000000981:diagnostic imaging; D009842:Oligopeptides / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography / Q000379:methods*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D014018:Tissue Distribution; D023041:Xenograft Model Antitumor Assays
chemical_list: D005462:Fluorine Radioisotopes; D009842:Oligopeptides; D019718:Receptors, CXCR4; C504129:TC14012
references: Appl Radiat Isot. 2011 Feb;69(2):410-4
references: 20965741
references: Bioorg Med Chem Lett. 2001 Jul 23;11(14):1897-902
references: 11459656
references: Blood. 2009 May 7;113(19):4604-13
references: 19228923
references: Nature. 2003 Sep 18;425(6955):307-11
references: 13679920
references: Theranostics. 2013;3(1):26-33
references: 23382783
references: J Nucl Med. 2011 Jun;52(6):986-93
references: 21622896
references: Cancer Res. 2010 May 15;70(10):3935-44
references: 20460522
references: J Med Chem. 2011 Nov 10;54(21):7648-62
references: 21905730
references: Nature. 2001 Mar 1;410(6824):50-6
references: 11242036
references: Cancer Res. 2007 Aug 1;67(15):7518-24
references: 17671223
references: Bioconjug Chem. 2011 Dec 21;22(12):2415-22
references: 22026940
references: J Control Release. 2012 Jan 30;157(2):216-23
references: 21964282
references: Cancer Res. 2002 Oct 15;62(20):5930-8
references: 12384559
references: Bioorg Med Chem. 2009 Feb 15;17(4):1486-93
references: 19188071
references: J Immunol. 2001 Oct 15;167(8):4747-57
references: 11591806
references: J Biol Chem. 2003 Jun 13;278(24):21631-8
references: 12690099
references: Theranostics. 2011;1:251-62
references: 21544263
references: Semin Cancer Biol. 2004 Jun;14(3):171-9
references: 15246052
references: J Exp Clin Cancer Res. 2008 Nov 04;27:62
references: 18983683
references: Bioorg Med Chem Lett. 2000 Dec 4;10(23):2633-7
references: 11128640
references: Bioorg Med Chem. 2012 Feb 15;20(4):1502-10
references: 22264762
references: Theranostics. 2013;3(1):34-9
references: 23382784
references: Clin Cancer Res. 2000 Sep;6(9):3530-5
references: 10999740
references: ChemMedChem. 2011 Oct 4;6(10):1789-91
references: 21780290
references: Theranostics. 2013;3(1):3-10
references: 23382780
references: Eur J Neurosci. 2000 Jan;12(1):117-25
references: 10651866
references: Nucl Med Biol. 2006 May;33(4):489-94
references: 16720240
references: Theranostics. 2013;3(1):11-7
references: 23382781
references: J Clin Endocrinol Metab. 2003 Jan;88(1):408-16
references: 12519884
references: Am J Pathol. 1997 Oct;151(4):1035-42
references: 9327737
references: Mol Imaging Biol. 2012 Feb;14(1):106-14
references: 21347799
references: Org Biomol Chem. 2003 Nov 7;1(21):3663-9
references: 14649897
references: J Nucl Med. 2010 Nov;51(11):1796-804
references: 20956475
references: Bioconjug Chem. 2011 May 18;22(5):859-64
references: 21480671
references: Blood. 2009 Apr 30;113(18):4341-51
references: 19139079
references: Eur J Immunol. 1997 Aug;27(8):2102-12
references: 9295051
references: Org Biomol Chem. 2003 Nov 7;1(21):3656-62
references: 14649896
references: Theranostics. 2013;3(1):40-6
references: 23382785
references: Mol Psychiatry. 1996 May;1(2):133-40
references: 9118323
references: J Natl Cancer Inst. 2000 Apr 19;92(8):628-35
references: 10772680
references: J Biol Chem. 2002 Dec 20;277(51):49481-7
references: 12388552